Form D Explorer
Quince Therapeutics, Inc. · CIK 1662774

Report a data issueCitable research briefCompare issuerPrivate research collection

Quince Therapeutics, Inc.

CIK 1662774 · Corporation · Inc. CALIFORNIA · South San Francisco, California · Biotechnology

Filing history at a glance

The two most recent stored filings share the date Jun 11, 2026. The filing dates alone do not show which came first. The displayed filing reports $7,387,671 offered. All 3 stored filings from Jul 1, 2025 to Jun 11, 2026 are original notices.

Filings
3
Original notices
3
Amendments
0
Activity
Jul 1, 2025
through Jun 11, 2026

Figures are issuer-reported and describe stored filings. Data coverage and methodology.

Differences between reported disclosures

Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.

Both filings have the same date. Their sequence is unknown; directional differences are suppressed.

Unavailable values are shown as a dash; reported zero remains zero.
FieldJun 11, 2026 · DJun 11, 2026 · DLater minus earlier
Reported offering amount$186,422,679$7,387,671—
Reported amount sold$114,720,542$0—
Reported investor count2766—
Reported minimum investment$0$0—

Earlier SEC source: 0000912282-26-000809 · Later SEC source: 0000912282-26-000811

Choose filings to compare · Research this issuer step by step

Latest available filing snapshot

Form D · Jun 11, 2026

Reported offering amount
$7,387,671
Reported exemptions
Rule 506(b)
Reported amount sold
$0

This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.

Filings by year

Submission counts, including amendments; not dollars raised or distinct funding rounds.

Shared EDGAR submitting account

These filings share an external submitting CIK in their accession numbers. The account may belong to a filing agent. How EDGAR assigns accession numbers.

Form D filings (3)